Epicatechin Used in the Treatment of Intestinal Inflammatory Disease: An Analysis by Experimental Models

Table 4

Macroscopic and microscopic scores of the colitic lesions of different groups submitted to the chronic colitis model with relapse.

	1st week score		2nd week score		3rd week score
	Macro	Micro	Macro	Micro	Macro	Micro
Non-colitic	0*	0*	0*	0*	0^*#	0^*#
TNBS control	6 (1.5)	18 (2)	6 (1.5)	19 (2.5)	5.5 (1.75)^#	18.5 (1)^#
EC 10	4 (1)*	14 (1.5)*	2 (1)*	13 (2)*	3 (1)*	15 (2)*
EC 50	4 (2.5)	16 (2.5)	3 (1)	15 (1.5)	4 (1.5)^#	16 (1.5)
Sulfasalazine	3.5 (2.5)	15.5 (2.5)	4 (1.5)	16 (1.5)	5 (2)^#	17 (2)^#
Not relapsed TNBS	—	—	—	—	2 (1)*	12 (1)*

Results expressed as median (interquartile range). Kruskal-Wallis-Mann-Whitney, *P < 0.05 comparing to TNBS group, ^#P < 0.05 comparing to not relapsed TNBS control. n = 4–7. EC 10 and 50: Epicatechin, dose 10 and 50 mg/kg.